A Review on Hemophilia it?s diagnostic tests and the application of Extending Half Life Products
Author(s): Manish Kumar Gupta*, Krishna Gopal, Anil Ahuja, Sudheesh Shukla and Ajay Bilandi
Abstract
Both haemophilia A as well as haemophilia B were X-linked congenital disorders which leads to bleeding owing to de?cec of coagulation factors in blood notably factor VIII (FVIII) and IX (FIX), respectively. Replacement treatment is chosen care option for those persons suffering from haemophilia. Prophylactic elimination of coagulation factor is the treatment of choice for patients with chronic condition; which have been proved to considerably reduce arthropathy, lowering number of bleeds, as well as boosting the patients' life quality. Normal recombinant factor prophylaxis needs with at minimum 2 (FIX) to 3 (FVIII) intravenous injections per week. Synthetic FVIII and FIX products with a longer half-life are being developed or have just been authorised. These products had documented average half-life increase of around 1.5 to 1.8 times than that compared to regular FVIII products as well as three to ?e times that of normal FIX products, thus, it possibly answers the demands of patients who are being treated by standard factor concentrations.